Background and Objectives In a previous pilot study, we demonstrated significantly lower haemoglobin (Hb) increment after red-blood-cell (RBC) transfusions in febrile patients compared to patients without fever. The aim of this study was to examine associations between inflammatory mediators and post-transfusion haemoglobin increment in patients with haematological diseases.
Introduction
Anaemia occurs frequently in hospitalised cancer patients. It decreases patients' quality of life (QOL) and may affect Correspondene: Dr. Øystein Wendelbo, Department of Medicine, Haukeland University Hospital N-5021 Bergen, Norway E-mail: oystein.wendelbo@helse-bergen.no treatment outcome [1] [2] [3] . In the 'European Cancer Anaemia Survey' (ECAS), 39 % of cancer patients were anaemic at inclusion, and 67% of the patients developed chemotherapy-induced cytopenia during a 6s-month observation period (anaemia was defined as haemoglobin (Hb) < 12 g/dl) [4] .
Treatment options for patients with chemotherapyinduced anaemia include erythropoiesis-stimulating agents and red-blood-cell (RBC) transfusions [5] . Platelet count increment after platelet transfusion is negatively affected by fever [6] , and preclinical studies indicate negative influence by fever on Hb increment after RBC transfusion also [7, 8] . Experimentally induced fever caused increased Hb content in the spleen in rabbits, without any signs of intravascular haemolysis [7] . RBCs stored for 35 days were more susceptible to fever than young red cells [7] . Red cell response to fever is dependent on the degree of fever and the effects may be counteracted by administration of corticosteroids [8] .
In a pilot study, we evaluated the corrected Hb increment after RBC transfusions in haematological patients with and without fever [9] .
The aims of this study were to analyse the levels of inflammatory mediators in plasma samples from the same patients that were studied in the previously published pilot study [9] , and to investigate whether different cytokine profiles in patients with and without fever receiving RBCs due to anaemia were associated with a difference in post-transfusion Hb increment in patients with haematological diseases.
Materials and methods
A prospective, observational study was performed. From June 2013 to May 2014 and from July 2015 to July 2016, adult patients (age ≥ 18) at the Section for Haematology, Department of Medicine, at Haukeland University Hospital with a haematological disease requiring RBC transfusion were screened for inclusion.
Patients included in the study demonstrated no sign of ongoing haemolysis. Haemodynamically unstable patients (ongoing bleeding or haemolysis) and patients with a positive direct antiglobulin test (DAT) were excluded. The study period lasted until hospital discharge, although patients were eligible for re-inclusion if they were later re-admitted to hospital. Indication for transfusion, Hb level (on the day of the transfusion), axillary temperature, height and weight were collected prior to transfusion. The patients and transfusion episodes were divided into two groups, 'fever' and 'no fever' (fever defined as an axillary temperature of ≥38°C). Pretransfusion samples for Hb and cytokines were collected in the morning of the transfusion day. Post-transfusion haemoglobin concentration was determined in a blood sample taken either shortly after transfusion (15-60 min) or the following morning. Hb increment corrected for estimated blood volume (EBV) and amount of Hb transfused was calculated as (delta Hb 9 10 9 EBV)/(Hb transfused), as previously described [9] . The amount of Hb in the RBC units was calculated by a noninvasive method based on net weight of the concentrates as earlier published [10] and patients' blood volume was estimated by the DuBois and DuBois formula [11] .
In accordance with hospital policy, all patients received leucocyte depleted and irradiated RBCs.
RBC characteristics
The RBC concentrates (SAGM erythrocyte concentrates) were produced according to the standard procedure at the Department of Immunology and Transfusion Medicine at Haukeland University Hospital (Cryofuge 5500i and 6000i (Thermo Fisher Scientific, Waltham, MA, USA) and Optipress II (Baxter, Chicago, IL, USA) in the first inclusion period and Reveos system (Terumo BCT, Lakewood, CO, USA) in the second inclusion period. All RBCs were leucocyte depleted by filtration before storage, and irradiated prior to transfusion. All were less than fourteen days old when they were irradiated, and maximum storage time after irradiation was until 28 days after collection. Prior to transfusion, the following data were collected for the RBCs to be transfused: ABO and Rh (D) type, net weight and storage duration. The Hb content was determined based on the net weight of the concentrates as described earlier [10] .
Preparation and preservation of plasma samples for cytokine analyses
Venous blood was drawn into citrate tubes (4 ml Vacuette Sodium Citrate tubes, Greiner Bio-One GmbH, Kremsm€ unster, Austria) by venepuncture. The blood samples were pipetted into Eppendorf tubes before they were centrifuged twice at 4°C for cytokine analysis: first at 2500 g for 15 min. Plasma was then pipetted into new Eppendorf tubes and centrifuged for 10 min at 10 000 g, before aliquoted and immediately frozen at -70°C until analysed.
Multiplex technology
Mediator levels were determined by multiplex analysis using the Bio-Plex Human Cytokine 27-plex kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). This kit includes the interleukins (IL) IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17 and interleukin-1 receptor antagonist (IL-1Ra), the chemokines CCL2, -3, -4, -5 and -11 and CXCL10, the growth factors basic fibroblast growth factor (FGF), platelet-derived growth factor (PDGF-BB), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF) and vascular endothelial growth factor (VEGF) and the immunomodulatory cytokines interferon-c (IFN-c) and tumour necrosis factor (TNF). All analyses were performed strictly according to the manufacturer's instructions.
Ethics
The study was approved by the local Ethics Committee (Regional Ethics Committee III, University of Bergen, Norway), and samples were collected after written informed consent.
Statistical and bioinformatical analysis
A mixed model analysis (MMA) was used to account for repeated measures. Twenty-seven patients were included; nine of them were included more than once. Most patients also had multiple measurements during an inclusion. Due to repeated measurements, t-tests could not be used. P-values ≤ 0Á05 were considered to be significant. The cytokine values were natural log (ln)-transformed before analysis to make the residuals more normally distributed. A mixed linear regression model assuming a compound symmetry correlation structure between repeated measurements from the same patient was used to; (1) compare characteristics of transfusion episodes between the two groups, (2) compare the pretransfusion CRP levels between the two groups, (3) compare the cytokine levels between the two groups, (4) investigate if there was an association between each cytokine, adjusted for fever, and corrected Hb increment.
Generalized estimating equations were used to test whether the proportion of patients transfused with platelet concentrates in addition to RBCs was independent of fever status. To investigate whether unsupervised hierarchical clustering based on biologically related mediators could be used to identify patients with fever, the Chi-Square test was used. To fulfil the assumptions of the model, only the first sample from each patient was included.
Bioinformatical analyses were performed using the JExpress (MolMine AS, Bergen, Norway) [12] . For hierarchical clustering, all values were median variance standardized and log2-transformed. The complete linkage was used as linkage method, and for distance measured, the Pearson correlation was used [12, 13] . Statistical analyses were performed using IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 7 (GraphPad Software, CA) was used for the figure presentation.
Results

Patient characteristics
Twenty-seven patients (eight women, 19 men) were included, and none of the patients were splenectomised. Fifteen patients were transfused only when they did not have fever, eight patients had transfusion episodes both with and without fever and four patients were transfused only when they had fever. A total number of 102 transfusion episodes, with 35 and 67 episodes in patients with and without fever, respectively, were evaluated.
Epidemiological data for the patient cohort are presented in Table 1 , and for the patients at each transfusion episode in Table 2 . The patients were diagnosed with a wide range of disorders, reflecting a consecutive and thereby unselected group of patients.
Pre-and post-transfusion Hb-levels differed between patients with and without fever Pre-and post-transfusion Hb-levels differed significantly between patients with and without fever ( Table 2 ). Pretransfusion Hb level was significantly higher in patients with fever compared to patients without fever (P = 0Á018), while post-transfusion Hb level was significantly lower in patients with fever (P = 0Á028). Consequently, patients with fever had significantly lower corrected Hb increment (mean corrected Hb increment 0Á48 g/dl) compared to patients without fever (mean corrected Hb increment 0Á71 g/dl, P = 0Á002). Table 1 Epidemiologic data for the 27 patients included in the study
Patient demographics
Results are reported as median and minimum-maximum or as number of observations (n) and per cent.
Pretransfusion CRP levels differed significantly between patients with and without fever
Febrile patients had significantly higher pretransfusion levels of CRP compared to patients without fever (115Á6 vs. 59Á6 mg/l, P < 0Á001, Fig. 1 ).Furthermore, a significant association between pretransfusion CRP level and corrected Hb increment was observed for the whole patient cohort (Fig. 2) . However, when fever was kept constant at either level, there was no significant association between pretransfusion CRP levels and corrected Hb increment within each of the two groups of patients.
Platelet transfusion was significantly associated with fever
Febrile patients received both RBCs and platelet concentrate (PC) in 23/35 transfusion episodes, whereas patients without fever were transfused with PC in addition to RBCs in 28/67 transfusion episodes. A statistically significant association between fever and platelet transfusion (OR: 2Á9, P < 0Á001) was found, indicating that there is a 2Á9 times increased probability that patients with fever are transfused with platelet concentrate compared to patients without fever. 
Hb increment adjusted for blood volume and Hb transfused Mean (SD) (min, max)
A mixed model analysis with fever (dichotomous variable, fever and no fever, fever defined as an axillary temperature ≥38°C) as predictor variable was used to account for repeated measures and for some patients being included more than once.
Values are given as mean, standard deviation (SD) and minimum-maximum. Means are estimated marginal means from mixed linear model analysis. 'Estimate no fever' gives the direction and magnitude of the difference between the two groups.
When the predictor variable 'fever' changes from 'fever' to 'no fever', the outcome variable changes with the size and direction of 'Estimate no fever' . For six of the twelve mediators (IL-6, IL-8, IL-10, CXCL10, CCL5 and G-CSF), a statistically significant difference between the two groups was detected ( Table 3) . Four of the mediators (IL-6, IL-8, IL-10 and G-CSF) demonstrated significantly higher values in febrile patients compared to nonfebrile patients, whereas CCL5 and CXCL10 were significantly lower in patients with fever (Table 3 and Fig. 3 ). These six mediators represent a heterogeneous group with regard to biological function and include the proinflammatory mediators IL-6, IL-8, CCL5, CXCL10 and G-CSF, and the anti-inflammatory mediator IL-10.
Unsupervised hierarchical clustering
To identify clusters of inflammatory mediators and investigate whether haematological patients with and without fever can be distinguished via such clusters, an unsupervised hierarchical cluster analysis of the inflammatory mediator profiles was performed.
The first plasma sample from each patient was included. Therefore, only 27 of totally 102 samples in the study were included in the cluster analysis. Eight of the samples were from patients with fever, and 19 samples from patients without fever. As previously demonstrated by MMA, six of the mediators (IL-6, IL-8, IL-10, CXCL10, CCL5 and G-CSF) were discriminative for patients with fever.
When clustering all 12 mediators, neither the febrile patients nor the plasma mediators localised into certain clusters (Fig. 4) . However, some soluble mediators clustered together with or close to related mediators: that is cluster 1: IL-1Ra, TNF, IFN-c and CCL2 and cluster 2: IL-6, IL-8 and G-CSF.
To investigate whether unsupervised hierarchical clustering based on biologically related mediators could be used to identify patients with fever, clustering analyses were performed, based on the six mediators that differed significantly between febrile and nonfebrile patients (Fig. 5) . The results demonstrated two clusters. In cluster (1) seven of 16 patients had fever, whereas in cluster (2) one of 11 patients had fever (Chi-Square test, P = 0Á053). Thus, even when the cluster analysis was based only on the six mediators showing statistically significant differences between patients with and without fever, the clustering cannot be used to separate patients with temperature -38°C.
Association between post-transfusion haemoglobin increment, plasma inflammatory mediators, and patient characteristics Axillary temperature was used as a dichotomous variable with the categories 'Fever' and 'No fever', where fever was defined as an axillary temperature of 38°C or more during the day. Sixty-seven samples were analysed from patients without fever, and 35 samples from patients with fever. The mixed model analysis of the impact of the patient characteristics age, gender and diagnosis revealed no significant association between patient characteristics and post-transfusion Hb increment. As the results of the analyses did not change much when these variables were removed, they were also omitted from further statistical analysis.
First, it was tested whether there was an association between each of the mediators and corrected Hb increment when adjusting for fever. Corrected Hb increment was outcome variable and each mediator and fever was predictor variables ( Table 4 ). The mediators were lntransformed to make the residuals more normally distributed to meet the assumptions of the statistical model.
The results of the MMA demonstrated that haematological patients with fever had a significantly lower corrected Hb increment compared to patients without fever, when adjusting for each of the 12 mediators (Table 4) . However, when fever was kept constant at either level, there was a significant negative association between Hb increment and the proinflammatory mediators IL-6 (P = 0Á002) and IL-8 (P = 0Á002), indicating that when fever is kept constant an increase in IL-6 or IL-8 results in a decrease in corrected Hb increment equivalent to the regression coefficient.
Discussion
In a previous pilot study [9] , we evaluated Hb increment after RBC transfusion by calculating the corrected Hb increment using the difference between pre-and posttransfusion values and correcting for the patient's blood volume and gram haemoglobin transfused in haematological patients with and without fever. The results indicated that Hb increment per unit was significantly lower in
No fever
Fever
Mediator levels were measured in 102 samples from 27 patients with haematological malignancies. Sixty-seven samples were analysed from patients without fever (dichotomous variable, fever and no fever, fever defined as axillary temperature <38°C), and 35 samples from patients with fever. MMA with each mediator as outcome variable and fever as predictor variable was used to account for repeated measures and for some of the patients being included more than once. The mediators were ln-transformed to make the residuals more normally distributed to meet the assumptions of the statistical model. Means are estimated marginal means from the MMA-analysis. All mediators were measured in picogram/millilitre (pg/ml). febrile patients receiving RBC transfusions than in patients without fever [9] . The aim of the present study was to investigate whether inflammatory mediators are associated with post-transfusion Hb increment. Fever in the patient cohort could be triggered by various reasons including cancer, infections, drug fever, thrombotic thrombocytopenic purpura and deep venous thrombosis. Inflammatory mediators involved in induction of the inflammatory response are the proinflammatory cytokines TNF, IL-1b, IL-6 and IL-8 and the anti-inflammatory cytokines IL-10 and IL-1Ra [14] [15] [16] [17] . Fever is mediated by the release of pyrogenic mediators such as TNF, IL-1, IL-6 [18] [19] [20] and interferons into the bloodstream in response to exogenous pyrogens. In this study, upregulated pretransfusion levels of IL-6 were found in haematological patients with fever compared to patients without fever; however, we found no significant differences in TNF. These results demonstrate that IL-6 was part of a broader inflammatory response which may be associated with a risk of reduced Hb increment after transfusion in patients with haematological disease.
CRP, an acute phase protein, is mainly synthesised by the hepatocytes in the liver in response to IL-6 [21] . Previous studies have demonstrated a strong correlation between CRP and IL-6 levels [22] . Elevated levels of serum CRP is observed with most invasive infections [23] . In addition, several other conditions contribute to elevated CRP concentrations including trauma, surgery, burns, tissue necrosis, immunologically mediated inflammatory diseases, crystal-induced inflammatory diseases and advanced cancer [21, 24] . We hypothesized that there exists a relationship between pretransfusion CRP level in patients with and without fever and post-transfusion Hb increment.
The results demonstrate that febrile patients have significantly higher pretransfusion CRP levels compared to patients without fever. A significant association between pretransfusion CRP levels and corrected Hb increment was also observed, indicating that an increase in CRP level results in a decrease in corrected Hb increment. However, when fever was kept constant at either level, there was no significant association between Fig. 3 Ln of plasma levels of the six inflammatory mediators that demonstrated significant differences between patients with (+) and without (-) fever. The P-values are calculated by mixed model analysis to account for repeated measures, and for patients being included more than once, and are indicated in the heading of the individual figures. The mean levels are marked as horizontal lines.
pretransfusion CRP level and corrected Hb increment within the 'fever' or the 'no fever' group, indicating that changes in temperature and not changes in pretransfusion CRP levels explained the changes in corrected Hb increment. Platelet concentrates contain soluble mediators derived from both platelets and contaminating leucocytes. During platelet transfusion, these mediators are transferred to the recipient. As platelet transfusions were more common in the febrile patient group, this could therefore influence our results. In a previous study by Apelseth et al. [25] , they investigated the effect of platelet transfusion on the systemic levels of inflammatory mediators in acute leukaemia patients with severe chemotherapy-induced cytopenia. Their results demonstrated altered levels of a number of soluble mediators, including a transient decreased level of IL-6 and increased plasma levels of CCL5. As the effects were mostly observed for only one hour, and the fact that IL-6 concentrations were reduced after platelet transfusion opposed to our finding of significantly increased IL-6 concentrations in febrile patients, the platelet transfusions should not affect our results. A statistically significant association between fever in the patient cohort and platelet transfusion (OR: 2Á9, P < 0Á001) was demonstrated, indicating that there is a 2Á9 times increased probability that patients with fever are transfused with platelet concentrate compared to patients without fever. When comparing pretransfusion levels of mediators between febrile and nonfebrile patients, there were increased levels of IL-6 and decreased levels of CCL5, indicating that platelet transfusions modulate the systemic cytokine network in acute leukaemia patients with chemotherapy-induced cytopenia.
When comparing pretransfusion levels of inflammatory mediators in febrile and nonfebrile patients, significantly higher levels of the proinflammatory cytokines IL-6, IL-8, the anti-inflammatory cytokine IL-10 and the growth factor G-CSF were found, whereas significantly reduced Fig. 4 Unsupervised hierarchical clustering analysis of plasma levels of the 12 mediators that showed detectable levels in all the 102 samples. The first plasma sample from each patient was included. Twenty-seven samples, eight samples from patients with fever, and 19 samples from patients without fever were included. Fever was defined as an axillary temperature ≥38°C. levels of the chemokines CCL5 and CXCL10 in patients with fever were observed. These results demonstrated a variety in range of inflammatory mediators. Previous studies have demonstrated elevated levels of TNF and IL-6 in patients with chemotherapy-induced cytopenia compared to healthy controls. This study compared pretransfusion levels of mediators in haematological patients with cytopenia with or without fever and did not include healthy controls. The results demonstrated altered levels of six inflammatory mediators. Thus, intensive chemotherapy does not cause a general depression of serum cytokine levels.
An unsupervised hierarchical clustering method was used to obtain a more complementary picture of the heterogeneous data set. This methodology was used to explore inflammatory mediators as well as patient covariates, as it gives an overview of both patient as well as covariates in one single picture that is difficult to obtain using traditional statistics. Twenty-seven samples were included in the analysis, one from each of the 27 patients. However, when performing unsupervised hierarchical clustering analysis, the results did not demonstrate statistically significant differences between patients with and without fever, which indicate that the clustering cannot be used to separate patients with and without fever (defined as axillary temperature >38°C).
Aims of the study were to look for associations between post-transfusion Hb increment, plasma inflammatory mediators in plasma samples and patient characteristics (age, gender and diagnosis). Neither gender and age nor diagnosis demonstrated any significant association with Hb increment and was omitted from further analysis. In the first analysis, the results demonstrated Fig. 5 Unsupervised hierarchical clustering analysis of plasma levels for the six inflammatory mediators that differed between the two groups. Twenty-seven plasma samples were included as follows: eight samples from patients with fever, and 19 samples from patients without fever. Fever was defined as an axillary temperature ≥38°C. 'changes from 'fever' to 'no fever', the outcome variable changes with the size and direction of 'Estimate no fever' . Table 4 Mixed model analysis to find if there was an association between each of the mediators and corrected Hb increment when adjusting for fever (dichotomous variable, fever and no fever, fever defined as an axillary temperature MMA was used to account for repeated measures and for some of the patients being included more than once.
Corrected Hb increment was outcome variable and each mediator and fever was predictor variables.
that when each of the mediators was kept constant at a certain value, febrile patients had a significantly lower corrected Hb increment compared to haematological patients without fever. However, when the temperature variable 'Fever'/'No fever' was kept constant at either of the two levels, only the cytokine IL-6 and chemokine IL-8 demonstrated a significant correlation between mediator level in plasma and corrected Hb increment in the patients. For both mediators, the patients with higher levels showed reduced corrected Hb increment after RBC transfusion. These results indicate the following: (1) when the P-value of Fever is < 0Á05 and the and the P-value of the mediator is > 0Á05, fever contributes to explain the lower Hb increment in febrile patients compared to nonfebrile haematological patients, and (2) when the P-values of both fever and the mediator are < 0Á05, both contribute independently of each other to explain the lower Hb increment in febrile patients. In this study, there was no fixed time for measuring the post-transfusion Hb increment. Some samples were collected shortly after the end of transfusion while most samples were collected the following morning. The median time from transfusion to sampling is therefore unfortunately not known. However, when exploring the data, the mean Hb increment from the samples collected shortly after transfusion was 0Á1 g/dl less than the mean Hb increment the following morning.
Conclusion
In conclusion, haematological patients with fever transfused with RBCs had significantly lower corrected Hb increment compared to patients without fever. Our results indicate that both fever and the inflammatory mediators IL-6 and IL-8 are associated with post-transfusion Hb increment. Future studies are needed to further characterise this inflammatory response and its clinical implications.
